1. Home
  2. XOS vs MCRB Comparison

XOS vs MCRB Comparison

Compare XOS & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xos Inc.

XOS

Xos Inc.

HOLD

Current Price

$1.56

Market Cap

38.1M

ML Signal

HOLD

Logo Seres Therapeutics Inc.

MCRB

Seres Therapeutics Inc.

HOLD

Current Price

$1.25

Market Cap

41.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XOS
MCRB
Founded
2016
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.1M
41.2M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
XOS
MCRB
Price
$1.56
$1.25
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$4.00
★ $17.00
AVG Volume (30 Days)
★ 102.4K
87.3K
Earning Date
11-12-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 59.49
N/A
EPS
★ N/A
N/A
Revenue
★ $45,992,000.00
$789,000.00
Revenue This Year
N/A
$1,648.67
Revenue Next Year
$90.13
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.58
$1.30
52 Week High
$8.27
$18.86

Technical Indicators

Market Signals
Indicator
XOS
MCRB
Relative Strength Index (RSI) 23.98 20.94
Support Level N/A N/A
Resistance Level $1.89 $2.26
Average True Range (ATR) 0.24 0.22
MACD -0.08 0.02
Stochastic Oscillator 2.51 2.74

Price Performance

Historical Comparison
XOS
MCRB

About XOS Xos Inc.

Xos Inc is a fleet electrification solutions provider committed to the decarbonization of commercial transportation. Xos designs and manufactures Class 5 through 8 battery-electric commercial vehicles that travel on last-mile, back-to-base routes of up to 200 miles per day. Xos also offers charging infrastructure products and services through Xos Energy Solutions to support electric vehicle fleets. Its products include Stepvan, MDXT, HDXT, Xosphere, and Xos Energy Solutions.

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.

Share on Social Networks: